Introduction {#sec1}
============

Given the ever-growing epidemics of obesity and weight-related health complications such as type 2 diabetes and cardiovascular disease, many studies have focused on understanding metabolic changes associated with overweight and obesity. However, novel insights on metabolic differences in humans might also come from studying people on the extreme opposite side of obesity, a state called constitutional thinness (CT). CT is characterized by a stable low BMI, generally \<18 kg/m^2^ ([@bib1], [@bib2]). Unlike in anorexia nervosa or other eating disorders associated with low weight, the nonpathological state of CT is defined by the lack of psychological features such as food aversion, refusal to eat alternated with binge eating, lower self-esteem, perfectionism, and body dissatisfaction ([@bib3]). In contrast to lipodystrophic and anorexic individuals, CT subjects have body fat mass percentages considered in the healthy range ([@bib4]), albeit lower than people generally considered lean (BMI: 19--24 kg/m^2^). Hormonal profiles are similar to those of lean subjects: they have no detectable abnormalities of cortisol, growth hormone, insulin-like growth factor 1, or free triiodothyronine secretory patterns ([@bib2]) and normal menstrual cycles ([@bib5]). Lower leptin levels were detected in CT individuals compared with lean women ([@bib3]). Daily calorie consumption is consistently similar in CT individuals and lean controls, while absolute resting metabolic rate is lower in CT individuals. In addition, CT women were found to be resistant to weight gain upon fat overfeeding ([@bib6])~.~ To date, however, none of the studies on CT shed light on the possible molecular mechanisms involved in this thin, weight-resistant phenotype. Moreover, clinical characterization has focused on female CT individuals only, while the CT phenotype also exists in males. In this study, we evaluated plasma and/or urinary proteins and metabolites before and after a 2-wk overfeeding intervention in both female and male CT individuals compared with lean, normal-weight participants. We also analyzed mitochondrial function and transcriptomic profiles in the adipose tissue and muscle from CT and control subjects. Our results postulate that CT individuals are characterized by an adipose tissue--specific higher mitochondrial function as well as distinct transcriptomic profiles, testifying for altered lipid metabolism in CT. This observation suggests that altered adipose tissue metabolic activity is a hallmark of the CT phenotype.

Methods {#sec2}
=======

Study participants and protocol {#sec2-1}
-------------------------------

A summary flowchart of the study design is shown in **[Supplemental Figure 1](#sup1){ref-type="supplementary-material"}**. Sixty-seven healthy young subjects, free of continuous medication, were recruited, of whom a total of 60 completed the study (dropouts: 1 female CT individual, 3 male CT individuals, 2 female controls, 1 male control). Of these 60 subjects, 30 were assigned as CT (defined as having a BMI ≤18.5 kg/m^2^ and recruited among outpatients consulting for body weight gain desire) and consisting of 15 females and 15 males. The low BMI and specific exclusion criteria ([@bib7]) such as parameters for liver metabolic dysfunction (**[Supplemental Table 1](#sup1){ref-type="supplementary-material"}**) and psychological profiling were used to define the CT status. For the control group, 30 people were included (with a BMI from 20 to 25 kg/m^2^), with 15 females and 15 males. All recruited participants were matched for age (18--35 y) and physical activity levels (PALs). The primary outcome variables for the study were molecular differences between CT individuals and controls before and after 14 d of overnutrition evaluated in plasma, urine, and fat and muscle biopsy specimens. Secondary outcome measures included metabolic, anthropometric, and histological and energy metabolism differences between CT individuals and controls before, during, and after 14 d of overnutrition. We refer to Ling et al. ([@bib7]) for the rationale and description of the clinical trial protocol, including the study design, measurement of body composition by DXA, bone quality by high-resolution peripheral quantitative computed tomography (HR-pQCT), and measurement of body core temperature and blood and urinary metabolites. Leptin was quantitatively measured with an ELISA kit (BioVendor). The detection limit was 1 ng/mL. Postprandial insulin and glucose responses were measured after an overnight fasting upon consumption of a standardized test meal \[1 bottle of Renutryl Booster (Nestlé Health Science) consumed slowly during 15 min under surveillance\]. Venous blood samples were collected in tubes containing aprotinin and EDTA at 7 time points: T~0~ = 0 min (after a 12-h overnight fasting), T~15 ~= 15 min (immediately after drinking the test meal), T~30~ = 30 min, T~60~ = 60 min, T~90~ = 90 min, T~120~ = 120 min, and T~150~ = 150 min. Total lipid content in stool was measured by near-infrared deflectance analysis (Fenir 8820; Perten) in homogenized samples. When stools were liquid, measurement of total lipids was done using traditional methods of titrimetry more appropriate than the near-infrared reflectance analysis method.

Overfeeding {#sec2-2}
-----------

After 2 wk of baseline assessments, all participants consumed a bottle of Renutryl Booster \[Nestlé Health Science; 72 g carbohydrates (48.5%), 30 g proteins (20%), and 21 g fat (31.5%)\] as an add-on to their usual food intake during 14 consecutive days, providing a 600-kcal surplus to their normal diet. Participants were required to consume the bottle in the interval of dinner to bedtime in free-living conditions and to maintain their usual dietary and normal lifestyle throughout the study. Body weight was measured throughout the study and was followed up at 2-wk postoverfeeding (ad libitum free-living period). Based on an earlier publication ([@bib6]), we achieved 78% power for weight difference detection using 30 subjects per group (2-sided *t* test, α = 5%).

Energy balance measurements {#sec2-3}
---------------------------

Energy variables were evaluated under 2 conditions. First, in free-living conditions, food intake was measured by recording 2 × 7-d food diaries (before and after overfeeding). An accelerometer (Actiheart; CamNtech) ([@bib8]) was used to monitor PALs in real life both at baseline and during overfeeding for 2 × 5 d. Resting energy expenditure (REE) was measured at a 12-h fasting state in the supine position by indirect calorimetry using a canopy (Quark RMR; COSMED) before and after the overfeeding ([@bib9]). Respiratory quotient (RQ) and fasting fat and carbohydrate oxidation rates were derived from the canopy. Free-living total energy expenditure (TEE) was obtained from TEE = REE × PAL. Second, the participants stayed for 2 visits (before and after overfeeding) in an open-circuit whole-body calorimetric chamber, where standardized meals were given, and energy expenditure was measured by monitoring continuously for 24-h O~2~ and CO~2~ levels ([@bib10], [@bib11]). REE was calculated as the 30-min average after waking up in the fasting state. As a complementary test to energy expenditure, internal body core temperature (Tc) was also measured by tracking with a noninvasive Jonah capsule temperature sensor (Respironic) ([@bib12]) for at least 3 h postingestion before and after the overfeeding period. Time point T0 starts in the fasted state, ∼45 min after ingestion of the sensor. Each time point is the average of 4 measurements per minute. The sensor was taken ∼60 min before starting a challenge with the meal test; hence, a drop in temperature was observed between 15 and 30 min and excluded from analysis so as not to confound the results.

Ethics {#sec2-4}
------

The study protocol was performed according to the Declaration of Helsinki, approved by the Ethics Committee France: ANSM (2013-A00590--45), and registered at [clinicaltrials.gov](http://www.clinicaltrials.gov) as NCT02004821.

Plasma proteomics {#sec2-5}
-----------------

Proteomic analysis was performed on 203 EDTA-plasma samples in a fasted state before (visit 1), during (visit 6), and 11 d after the overfeeding intervention (visit 9) ([@bib7]) using LC-MS/MS. Full details characterizing the workflow and describing the laboratory method were previously reported ([@bib13], [@bib14]). LC-MS/MS was performed with an Orbitrap Fusion Lumos Tribrid mass spectrometer and an Ultimate 3000 RSLC nano system (Thermo Scientific). Protein identification was performed against the human UniProtKB/Swiss-Prot database (26/10/2015 release) as previously described ([@bib14]). A total of 999 proteins were measured. Biological references (identical pools of all individual plasma samples) were used to obtain relative protein quantification in each sample. A maximum of 30% missing quantitative values per protein was accepted. To identify proteins associated with the group classification (CT or control), the following logistic regression was fitted for each measured protein: Group ∼ LogFC_p~i~ + sex + age (to assess the effect of protein expression) both at baseline and after the intervention. A Wald test was performed to assess the statistical significance of the coefficient of interest, LogFC_p~i~, which corresponds to the base 2 logarithm of the ith protein ratio fold changes (FCs) with respect to biological references. Multiple testing correction was applied within each fitted model on the derived *P* values Benjamini--Hochberg False Discovery Rate (BH-FDR). A differential effect of the intervention on levels of proteins was evaluated using an ANOVA for repeated measurement testing an interaction between the period (time) and the CT status.

Adipose and muscle biopsies {#sec2-6}
---------------------------

Biopsies were carried out under local anesthesia. Human abdominal subcutaneous white adipose tissue (sWAT) samples were obtained from an area beneath the umbilicus by incision. Biopsied sWAT was immersed immediately in 2 mL ice-cold BIOPS (biopsy preservation solution) buffer on ice and split in several samples for histological, omics, and respiration assays. Muscle biopsy specimens were taken from the vastus lateralis by incision, gently removing the tissue to avoid contraction of muscle fibers. One part was immediately further analyzed for respiration, while another part was snap-frozen for subsequent later transcriptomic analyses.

Mitochondrial respiration {#sec2-7}
-------------------------

Mitochondrial respiration assessment was carried out within 3 h after the biopsy was taken using the OROBOROS high-resolution respirometry (Oxygraph-2k; Oroboros Instruments) before and after overfeeding (sWAT from 5 female CT individuals, 5 male CT individuals, 9 female controls, and 4 male controls and muscle from 4 female CT individuals, 5 male CT individuals, 4 female controls, and 4 male controls). The protocol was used as previously described ([@bib15]) to evaluate leak, complex I (CI), CI and complex II (CII), CII, and maximal electron transport system (ETS) respiration. Respirometry medium (MiR05) was used for the assay and was prepared as described by OROBOROS protocols ([@bib16], [@bib17]).

Staining and imaging of adipose tissue {#sec2-8}
--------------------------------------

Tissues were collected, fixed, and stabilized using Paxgene tissue containers (Qiagen) and paraffin embedded and sectioned (4 μm). Hematoxylin and eosin (H&E) staining was performed to determine adipocyte area. Slides were scanned with the Aperio AT2 (Leica; 20×amplification). Ten to 12 images (containing at least 80 adipocytes per image) were evaluated per sample using the Adiposoft software ([@bib18]) in a semiautomated fashion with manual removal of false positives and negatives (including removal of areas \<350 μm^2^). To evaluate the size distribution frequency, histograms were made by grouping areas from 350 to 15,000 in 500-μm^2^ increments.

Immunohistochemistry for uncoupling protein 1 (UCP1) was performed with primary polyclonal rabbit UCP1 antibody (dilution 1:20, 1-UN009--07; Quartett) on paraffin-embedded tissue sections using an automated immunostainer (BOND-III; Leica Biosystems). As positive control, we used human brown adipose tissue (BAT), taken from around the adrenal gland of a male newborn.

Mitochondrial DNA quantification {#sec2-9}
--------------------------------

Mitochondrial DNA (mtDNA) content analysis in baseline adipose tissue was carried out by quantitative real-time PCR. Briefly, DNA was extracted from the sWAT samples by the classical phenol/chloroform extraction method, and TaqMan real-time PCR was performed on the LightCycler 480 (Roche) using primers specific to human mtDNA in the *MT-RNR2* and *MT-ND4* genes and primers specific to *ALB* and *TFRC*, single-copy genes taken as nuclear gene references, as described in Marquis et al. ([@bib19]).

Gene expression analysis by RNA sequencing {#sec2-10}
------------------------------------------

Total RNA was extracted by pulverizing tissues using a Cryoprep CP02 and TT1 bags (Covaris). Then, ∼10 mg powdered muscle or ∼100 mg powdered adipose tissue, respectively, was introduced in a Lysing Matrix D tube (MP Biomedicals) placed on ice. Next, 500 *µ*L lysis buffer (Agencourt RNAdvance Tissue Kit; Beckman Coulter) was added. The tubes were firmly closed and agitated for 2 × 1 min at speed 6 on a FastPrep-24 (MP Biomedicals). RNA was then extracted using the Agencourt RNAdvance Tissue Kit (Beckman Coulter) following the provider\'s recommendations and quantified using the Quant-iT RiboGreen RNA Assay Kit (Invitrogen) on a Spectramax M2 (Molecular Devices). RNA quality was assessed using a Fragment Analyzer 96 with a Standard Sensitivity RNA Analysis Kit (Advanced Analytical Technologies). Sequencing libraries were prepared from 250 ng total RNA using the TruSeq Stranded Total HT Gold Kit (Illumina) with the Ribo-Zero Gold depletion set. The procedure was automated on a Sciclone NGS Workstation (Perkin Elmer). The manufacturer\'s protocol was followed, except for the PCR amplification step. The latter was run for 12 cycles with the KAPA HiFi HotStart ReadyMix (Kapa BioSystems). This optimal PCR cycle number has been evaluated using the cycler correction factor method as described previously ([@bib20]). Purified libraries were quantified with Picogreen (Life Technologies), and the size pattern was controlled with the DNA High Sensitivity Reagent kit on a LabChip GX (Perkin Elmer). Libraries were then pooled by 62. Four pools were generated, and each pool was clustered at a concentration of 9 pmol on 8 lanes of v4 high-output paired-end sequencing flow cells (Illumina). Ten flow cells were necessary to obtain the necessary read depth. Sequencing was performed for 2 × 125 cycles on a HiSeq 2500 strictly following Illumina\'s recommendations.

The demultiplexing and the quality control steps were performed as described in Armenise et al. ([@bib21]). Briefly, sequencing data were demultiplexed with the Bcl2FastQ Demux Pipeline (UBP\_ bcl2fastq v2.19.1). The resulting FASTQ files were mapped onto the human genome (GRCh37.75 assembly) with STAR2.5.3a using default parameters. Multimapper reads, PCR duplicates, and reads with more than 5 mismatches were filtered out. For each sample, the number of reads mapping onto genes was retrieved using HTSEq software. Only reads with both ends mapping onto 1 single gene were considered. Low expressed genes were excluded by using the threshold of at least 1 count per million in a third of the samples. Counts were transformed using the voom transformation ([@bib22]). To identify genes associated with the group classification (CT or control), the following logistic regressions were fitted for each measured gene: *1*) group ∼ transformed count gene~i~ + sex + age (to assess the effect of gene expression), and *2*) group ∼ transformed count gene~i~sex + age (to assess interaction between gene expression and sex). A Wald test was performed to assess the statistical significance of the coefficient of interest (either transformed count gene~i~ for model 1 or the interaction term for model 2). Multiple testing correction was applied within each fitted model on the derived *P* values (BH-FDR).

For differential expression analyses after the overfeeding intervention, the difference between postintervention and baseline was derived as follows: transformed counts after overfeeding -- transformed counts at baseline (LogFC_count). Logistic regressions were fitted as before: group ∼ LogFC_count + sex + age and group ∼ LogFC_countsex + age. Pathway and Gene Ontology (GO) enrichment analysis was performed within Ingenuity Pathway Analysis (Qiagen Bioinformatics), as well as Enrichr ([@bib23]). Genes that passed the false discovery rate (FDR)--adjusted *P* value \< 10% were used as the input data.

Validation of gene expression using Nanostring {#sec2-11}
----------------------------------------------

Gene expression was validated using Nanostring technology. The RNA samples derived from adipose tissue at baseline were used. Probes were designed for the top 62 genes differentially expressed in baseline adipose tissue samples between CT and control individuals from RNA sequencing (RNA-seq) analysis, as well as 9 normalization genes (manually selected based on stable expression in RNA-seq analysis and covering a range of expression levels). Normalization was performed by the Nanostring software. Principal component analysis of the expression FC on the quality-controlled data set did not identify any outliers. For all genes, a correlation test between RNA-seq and Nanostring gene quantification was performed using a nonparametric Spearman correlation test. Benjamini--Hochberg multiple testing correction was applied on corresponding *P* values.

Statistical analysis of clinical and molecular variables {#sec2-12}
--------------------------------------------------------

Statistical analyses were performed using R version 3.4.3. Quality control checking of the data was performed to measure missing values proportion and identify outliers by using the IQR range with values set as missing if out of the mean ± 3 × IQR range. Because of technical issues, data from 2 participants were excluded (1 control male and 1 CT female). A 2-way ANOVA for repeated measures with age and sex as covariates was conducted with each of the biochemical measures. The effect of group (CT and control status), time (pre- compared with postintervention), and group × time interaction was examined. A sex interacting effect was also added to the model. A group × time interaction measured a different change of the measure over the intervention in the 2 groups. For plasma kinetics of insulin and glucose up to 150 min postingestion of the test meal and internal body temperature, a 3-way repeated-measures ANOVA was used with age and sex as covariates. A logistic regression with age and sex as confounders and sex as interaction term was used to test the association between the status and blood biochemical outcome available at baseline only. For each set of measures (vital signs, lipid metabolism, glucose metabolism, blood and urinary biochemistry, energy variables), a Bonferroni correction was considered to account for multiple testing.

Results {#sec3}
=======

Clinical characterization of CT individuals at baseline {#sec3-1}
-------------------------------------------------------

[**Table 1**](#tbl1){ref-type="table"} summarizes the results of the clinical characterization of the subjects at baseline. As a sex interaction was not observed for most variables, we combined both sexes within each group. Total fat and lean mass were lower in CT individuals compared with controls (both in absolute and relative terms). We also identified lower systolic and diastolic blood pressure in CT individuals compared with controls. To exclude that the lower weight in CT individuals might be related to defects in gastrointestinal fat absorption, such as steatorrhea, we evaluated potential excess accumulation of fat in the feces ([@bib24]). However, neither visual inspection by the Bristol stool scale nor fat quantification in the stool showed any differences between the groups. Food intake was not different between the 2 groups, both in free-living as well as in the calorimetric chambers, and the proportions for each macronutrient category were similar between the groups (consisting on average of 48% carbohydrates, 37% lipids, and 15% protein relative caloric intake). Snacking frequency and snacking caloric intake were significantly higher in CT individuals than controls, confirming previous results ([@bib6]). Based on Actiheart measurements, we did not observe higher spontaneous physical activity in CT compared with control individuals. Rather, CT individuals had lower physical activity compared with controls. Both REE and TEE were significantly lower in CT individuals compared with controls in both free-living and calorimetric chamber conditions, but this difference was blunted when correcting for fat-free mass (*P* = 0.92 in canopy and *P* = 0.12 in the calorimetric chamber) (**[Supplemental Figure 2](#sup1){ref-type="supplementary-material"}**). Fasting RQ by canopy measurement was similar between CT individuals and controls while fasting fat oxidation rate was higher in CT individuals than controls, and the carbohydrate oxidation index was highly variable and nominally higher in CT individuals. To complement standard energy expenditure measures, we also tracked internal Tc for 3 h postingestion with a noninvasive Jonah capsule temperature sensor. Overall results show a slightly higher Tc in CT individuals compared with controls at baseline (**[Supplemental Figure 3](#sup1){ref-type="supplementary-material"}**A; ANOVA, *P* = 0.0087), with an average increase of +0.14°C pre- and postmeal.

###### 

Clinical variables in CT (*n* = 29, 14 females and 15 males) compared with control (*n* = 29, 15 females and 14 males) individuals at baseline [^1^](#tb1fn1){ref-type="table-fn"}

  Characteristic                              CT                 Control            CT status, *P*     CT status × sex, *P*
  ------------------------------------------- ------------------ ------------------ ------------------ ----------------------
  Age, y                                      24.97 ± 4.7        22.63 ± 2.93                          
  BMI, kg/m^2^                                16.96 ± 0.74       22.99 ± 1.03                          
  Waist-hip ratio                             0.77 ± 0.06        0.78 ± 0.07        0.042              0.28
  Total fat, kg                               9.71 ± 1.86        18.71 ± 5.20       1.7 × 10^−23^\*    0.98
  Total fat body mass, %                      19.59 ± 4.97       27.09 ± 7.89       4.5 × 10^−08^\*    0.53
  Total lean body mass, kg                    39.28 ± 6.70       49.79 ± 9.70       2.0 × 10^−26^\*    0.72
  Total lean body mass, %                     80.41 ± 4.97       72.56 ± 8.13       4.4 × 10^−08^\*    0.61
  Heart rate, bpm                             69.21 ± 10.68      65.28 ± 10.38      0.033              0.031
  Systolic blood pressure, mm Hg              115.07 ± 11.86     125.72 ± 9.83      4.2 × 10^−05^\*    0.17
  Diastolic blood pressure, mm Hg             66.21 ± 9.36       71.21 ± 6.67       6.0 × 10^−04^\*    0.079
  Fat stool, g/24 h                           3.16 ± 2.13        4.14 ± 2.31        0.25               0.39
  Energy variables                                                                                     
   Free-living condition                                                                               
    Total caloric intake, kcal/24 h           2179.62 ± 433.09   2004.55 ± 482.75   0.45               0.062
    Carbohydrates, g                          264.14 ± 65.22     227 ± 58.01        0.16               0.036
    Protein, g                                79.48 ± 19.53      80.34 ± 20.24      0.3                0.053
    Lipids, g                                 88.52 ± 18.64      81.38 ± 20.24      0.77               0.23
    Snacking calories, kcal/24 h              328.2 ± 192.67     177.08 ± 138.82    2.1 × 10^−03^\*    0.82
    Snacking frequency                        1.47 ± 0.72        0.95 ± 0.48        7.7 × 10^−03^\*    0.88
    Physical activity level                   1.55 ± 0.21        1.75 ± 0.21        9.1 × 10^−04^\*    0.016
    Fasting respiratory quotient              0.82 ± 0.04        0.8 ± 0.05         0.6                0.07
    Fat oxidation index, mg/min/kg            1.00 ± 0.31        0.91 ± 0.27        0.016\*            0.027
    Carbohydrate oxidation index, mg/min/kg   1.34 ± 0.84        0.80 ± 0.59        0.022              0.16
    REE, kcal/24 h                            1255.14 ± 228.91   1466.83 ± 239.82   1.4 × 10^−10^\*    0.62
    TEE, kcal/24 h                            1966.14 ± 458.79   2561.8 ± 591.65    2.5 × 10^−10^\*    0.15
   Calorimetric chamber                                                                                
    Total caloric intake, kcal/24 h           1919.71 ± 267.5    2007.39 ± 235.53   0.025              0.800
    REE, kcal/24 h                            1442.53 ± 386.89   1653.98 ± 331.45   8.10 × 10^−08\*^   0.62
    TEE, kcal/24 h                            1819.77 ± 243.94   2180.2 ± 284.21    9.10 × 10^−20\*^   0.88
  Lipid metabolism                                                                                     
   Cholesterol, mmol/L                        4.46 ± 0.78        4.13 ± 0.78        0.74               0.29
   HDL-C, mmol/L                              1.55 ± 0.36        1.36 ± 0.35        0.18               0.82
   LDL-C, mmol/L                              2.48 ± 0.76        2.30 ± 0.72        0.83               0.55
   Triglycerides, mmol/L                      0.93 ± 0.26        0.87 ± 0.29        0.59               0.33
   Glycerol, μmol/L                           31.24 ± 28.47      23.78 ± 20.08      0.55               0.19
    NEFAs, μmol/L                             389.97 ± 202.38    372 ± 223.82       0.29               0.71
  Glucose metabolism                                                                                   
   Fasting glucose, mmol/L                    4.66 ± 0.34        4.68 ± 0.44        0.81               0.46
   Fasting insulin, mUI/L                     6.07 ± 3.67        7.51 ± 2.75        5.7 × 10^−04^\*    0.36
  Blood biochemical parameters                                                                         
   IGF-1, µg/L                                241.62 ± 86.59     254.8 ± 52.51      0.033              0.097
   Leptin, µg/L                               3.76 ± 2.23        9.34 ± 6.77        0.34               0.27
   Metadrenaline, nmol/L                      0.20 ± 0.09        0.16 ± 0.06        0.18               0.75
   Normetadrenaline, nmol/L                   0.38 ± 0.11        0.34 ± 0.1         0.11               0.063
   TSH, mUI/L                                 2.38 ± 1.31        2.06 ± 1.01        0.38               0.33
   Free T3, pmol/L                            5.98 ± 1.99        5.44 ± 0.66        0.66               0.52
   Free T4, pmol/L                            16.83 ± 3.38       17.21 ± 1.68       0.99               0.2
  Urinary metabolites                                                                                  
   Creatinine, mmol/L                         10.05 ± 2.78       13.75 ± 3.6        4.7 × 10^−11^\*    0.56
   Urea, mmol/L                               263.11 ± 95.08     385.52 ± 143.25    3.5 × 10^−09^\*    0.17
   Uric acid, mmol/L                          2.62 ± 0.78        3.53 ± 0.94        7.0 × 10^−09^\*    0.92

Data are presented as means ± SDs. *P* values are assessed by repeated-measures ANOVA for outcomes adjusted for sex and age. A Bonferroni correction was applied for each set of measure to define a result as significant (defined by \*). bpm, beats per minute; CT, constitutional thinness; HDL-C, HDL cholesterol; IGF-1, insulin-like growth factor 1; LDL-C, LDL cholesterol; NEFA, nonesterified fatty acid; REE, resting energy expenditure; TEE, total energy expenditure; TSH, thyrotropin; T3, triiodothyronine; T4, thyroxine.

Assessment of bone quality of the radius and tibia by HR-pQCT demonstrated that many bone quality parameters were lower in CT individuals compared with controls, with the main differences observed in tibia (**[Supplemental Table 2](#sup1){ref-type="supplementary-material"}**), confirming previous results in females ([@bib25]). The lower bone quality was observed in both sexes.

At baseline, on the molecular level, circulating lipid metabolites, including cholesterol, triglycerides, free fatty acids, and fasting and postprandial kinetics of glucose and kinetics of insulin, were similar between the groups ([Table 1](#tbl1){ref-type="table"}, [Supplemental Figure 3B and 3C](#sup1){ref-type="supplementary-material"}), confirming previous results ([@bib2]), while fasting insulin levels were lower in CT individuals. Measured urinary metabolites, including urea, creatinine, and uric acid, were significantly lower in CT individuals than control subjects (FC 0.68, 0.73, and 0.74, respectively). Untargeted proteomic analyses of the plasma samples revealed 11 proteins that were differentially abundant between CT individuals and controls at baseline (**[Supplemental Table 3](#sup1){ref-type="supplementary-material"}**), including insulin-like growth factor binding protein 2 and dopamine *β*-hydroxylase (DBH) among the top plasma proteins with increased levels in CT individuals compared with controls.

Molecular analyses of adipose tissue and muscle demonstrate a distinct adipose-specific mitochondrial signature in CT {#sec3-2}
---------------------------------------------------------------------------------------------------------------------

To characterize the metabolic state of CT individuals in more depth, we next performed analyses on 2 key metabolic tissues, adipose tissue and muscle. H&E staining of the sWAT did not reveal any visual difference in terms of extracellular matrix remodeling or inflammation. CT individuals had a marked smaller adipocyte size (black bars, 2174 ± 142 μm^2^) compared with controls (white bars, 3586 ± 216 μm^2^) at baseline (*P* \< 0.001) ([**Figure 1**A](#fig1){ref-type="fig"}). This decrease was reflected by a higher frequency of small adipocytes in CT individuals (**[Supplemental Figure 4](#sup1){ref-type="supplementary-material"}**). In addition, males overall had on average smaller adipocytes than their female counterparts (males, 2666 ± 253 μm^2^; females, 3067 ± 197 μm^2^) (*P* \< 0.05) ([Figure 1A](#fig1){ref-type="fig"}). We then evaluated the mitochondrial function through high-resolution respirometry analyses in both sWAT and skeletal muscle. The oxygen fluxes during leak respiration---independent of ADP-phosphorylating activity---were similar between CT individuals and controls ([Figure 1B](#fig1){ref-type="fig"}), suggesting that there was no difference in uncoupling. Immunohistochemical staining of UCP1 also revealed the lack of presence of UCP1 in the sWAT samples compared with a human BAT sample used as positive control (**[Supplemental Figure 5](#sup1){ref-type="supplementary-material"}**). Interestingly, we observed significantly higher mitochondrial CII activity in CT individuals (FC 2.17, *P* = 0.001), as well as CI + CII activity (FC 1.71, *P* = 0.03) and maximal ETS activity (FC 2.07, *P* = 0.001) compared with controls. No significant difference in mitochondrial activity was detected between males and females. To evaluate if the increase in CII and ETS activity was due to an increase in mitochondrial number, we performed a quantitative mtDNA assay (defined as ratio of mitochondrial compared with nuclear DNA). The results showed a significantly higher amount of mtDNA per adipocyte (CT 784 ± 27 mtDNA molecules compared with control 675 ± 30 mtDNA molecules per cell) (*P* = 0.02) ([Figure 1C](#fig1){ref-type="fig"}), with no sex difference observed. This suggests that adipocytes of CT individuals have an increased number of mitochondria and that this contributes, at least in part, to the increased CII and ETS activity observed in CT. In skeletal muscle, uncoupled respiration (leak) was not different in CT individuals compared with controls (**[Supplemental Figure 6](#sup1){ref-type="supplementary-material"}**). Similarly, maximal respiration in the coupled state, with electron input through CI alone, CI and CII, CII alone, or maximal ETS capacity, was comparable between CT individuals and controls, even though there was a tendency toward lower CI and CII and ETS capacity, but it was not statistically significant. This suggests that the higher mitochondrial activity and content observed in sWAT of CT individuals are not due to a systemic difference in mitochondrial regulation, but rather are specific to the white adipose tissue.

![Distinct differences in adipose tissue in constitutional thinness (CT). (A) Adipocyte area (μm^2^) measured by histological analysis. Values are expressed as mean and SEM. Mean values are from at least 10 pictures per slide (capturing more than 1000 cells per sample). Black bars correspond to CT individuals ( *n* = 29, 15 females and 14 males), while white bars correspond to the controls (*n* = 29, 15 females and 14 males). (B) Respirometry analyses in subcutaneous white adipose tissue (sWAT) using high-resolution respirometry. Values are expressed as mean and SEM from 10 CT individuals (5 females, 5 males; black bars) and 13 controls (9 females, 4 males; white bars) before and after overfeeding (OF; dashed bars). CI, complex I respiration; CI + CII, complex I and II respiration; CII, complex II activity alone; ETS, maximal electron transport system capacity. (C) Mitochondrial DNA content in sWAT at baseline in CT individuals ( *n* = 29) compared with controls (*n* = 29). Associations between CT status and variables were tested using a logistic regression adjusted on confounders (age and sex) at baseline and after intervention. Statistical significance level after correction for multiple testing when comparing CT versus controls is indicated by \* for *P* \< 0.05 and \*\* for *P* \< 0.01, while ^\#^ indicates a significance level at *P* \< 0.05 of the intervention (before vs after intervention).](nqz144fig1){#fig1}

Transcriptomic profiling of adipose tissue and muscle confirm altered lipid metabolism in CT {#sec3-3}
--------------------------------------------------------------------------------------------

To gain further insights into the molecular basis of the observed differences in mitochondrial respiration and content, we profiled the RNA expression levels of the sWAT and muscle by total RNA-seq. Comparison of the expression profiles in sWAT revealed significant differences between the 2 groups ([**Figure 2**A](#fig2){ref-type="fig"}). We did not observe any sex differences in the gene expression profiles. Using an FDR of 0.1 and a log~2~ FC threshold of 0.75, we identified 88 Ensembl gene IDs (ENSG) differentially expressed between CT individuals and controls, of which 62 corresponded to annotated genes. To validate the gene expression results, we designed probes for those 62 genes and assessed gene expression by Nanostring technology. RNA-seq and Nanostring data amply correlated ([Figure 2B](#fig2){ref-type="fig"}, Spearman\'s *r* = 0.8926, *P* \< 0.0001), and 54 genes passed the threshold FDR of 0.1, corresponding to a validation of 87% of the RNA-seq results. Given the higher number of mitochondria found in CT, we first performed a GO cellular component enrichment analysis and found 21 terms that had a significant adjusted *P* value lower than 0.01, of which 9 belonged to the mitochondria (**[Supplemental Table 4](#sup1){ref-type="supplementary-material"}**), showing indeed an enrichment in genes belonging to the mitochondrial cellular component. In parallel, pathway analyses of the entire data set revealed increased oxidative metabolism as evidenced by significant upregulation of fatty acid oxidation but strikingly also triglyceride biosynthesis ([Figure 2C](#fig2){ref-type="fig"}). In addition, the IL-8 signaling pathway was reduced. IL-8 is a key proinflammatory mediator, known to be associated with obesity ([@bib26]). Enrichment using the MGI Mammalian Phenotype identified nominal enrichment in abnormal lipid levels (MP0001547), decreased body fat amount (MP0010025), and other interesting enrichments such as altered angiogenesis (MP0000260) and improved glucose tolerance (MP0005292) (**[Supplemental Table 5](#sup1){ref-type="supplementary-material"}**). Consistently, by zooming in on the specific top differentially expressed genes ([**Table 2**](#tbl2){ref-type="table"}), we found that many of the differences were associated with known positive metabolic outcomes in CT. These included decreased *LEP, EGFL6, MMP9*, and *HSD11B1*; elevated *APOC1*; and increased fatty acid synthesis, including elevated expression of *FASN, SCD, ELOVL6*, and *AACS*. Several antiangiogenic factors (*THBS1, TNMD*, and *EGFL6*), as well as oxidative stress factors (*HSPB7, CRYAB*, and *UCHL1*), were significantly downregulated. In addition, we identified multiple differentially expressed genes that have not been previously described for a potential role in metabolism. RNA-seq profiling in skeletal muscle samples did not reveal any significantly differentially expressed genes between CT individuals and controls (passing FDR of 0.1) (**[Supplemental Figure 7](#sup1){ref-type="supplementary-material"}**). The lack of robust transcriptomic alterations in the muscle is in line with the fact that respiration in CT muscle is not significantly affected either. We therefore postulate that the molecular signature correlating with the CT phenotype is most likely specifically linked to an alteration in lipid metabolism in the adipose tissue rather than a systemic difference in mitochondrial biogenesis affecting other metabolically active tissues as well.

![Transcriptomic analyses of adipose tissue at baseline. (A) Volcano plot showing differential expression of constitutional thinness (CT) (*n* = 30) compared with control (*n* = 30) individuals. Dashed lines correspond to the log~2~ fold change (FC) and false discovery rate (FDR) of 10%. The top differentially expressed hits are represented by orange dots, the significant hits but not strongly differentially expressed are represented by dark blue dots, and the nonsignificant hits not selected are represented by light blue dots. Differential expression was tested by using a logistic regression model correcting for age and sex followed by a Wald test to assess the statistical significance of the coefficient of interest. As no sex interaction was found, association was evaluated without interaction term. Benjamini--Hochberg multiple testing correction was applied within the fitted model on the derived *P* values (FDR). (B) Correlation is shown between RNA sequencing (RNA-seq) and Nanostring gene expression analysis of top 65 differentially expressed genes, tested using a nonparametric Spearman correlation (Spearman\'s *r* = 0.8926; 95% CI: 0.82, 0.94; *P* \< 0.0001). (C) Ingenuity Pathway Analysis showing the top 5 significantly affected pathways. Genes that passed the FDR-adjusted *P* value \< 10% were used as input data (orange and dark blue dots in the volcano plot, corresponding to 753 genes). Percentage overlap with the corresponding pathway is shown, as well as the number of hits compared with total number of genes in the pathway in parentheses.](nqz144fig2){#fig2}

###### 

List of genes differentially expressed in adipose tissue at baseline from CT (*n* = 30) compared with control (*n* = 30) individuals at baseline[^1^](#tb2fn1){ref-type="table-fn"}

                                                                                     RNA-seq    Nanostring                                  
  ----------------- ------------ --------------------------------------------------- ---------- ---------------- --------- ---------------- ----------------
  ENSG00000198759   *EGFL6*      Epidermal GF-like domain multiple 6                 --2.422    7.78 × 10^−02^   --1.829   1.17 × 10^−02^   7.10 × 10^−10^
  ENSG00000119125   *GDA*        Guanine deaminase                                   --2.392    7.78 × 10^−02^   --1.947   1.87 × 10^−02^   2.50 × 10^−13^
  ENSG00000123119   *NECAB1*     *N*-terminal EF-hand calcium binding protein 1      --2.355    7.78 × 10^−02^   --3.142   7.00 × 10^−03^   6.00 × 10^−31^
  ENSG00000100985   *MMP9*       Matrix metallopeptidase 9                           --1.83     8.02 × 10^−02^   --1.423   1.47 × 10^−02^   1.20 × 10^−10^
  ENSG00000113389   *NPR3*       Natriuretic peptide receptor 3                      --1.519    7.78 × 10^−02^   --1.683   5.49 × 10^−03^   2.20 × 10^−16^
  ENSG00000079689   *SCGN*       Secretagogin, EF-hand calcium binding protein       --1.293    7.78 × 10^−02^   --0.627   5.43 × 10^−02^   2.20 × 10^−16^
  ENSG00000174697   *LEP*        Leptin                                              --1.243    7.78 × 10^−02^   --1.214   3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000154277   *UCHL1*      Ubiquitin C-terminal hydrolase L1                   --1.218    7.78 × 10^−02^   --1.081   4.25 × 10^−03^   7.40 × 10^−31^
  ENSG00000182255   *KCNA4*      Potassium voltage-gated channel subfamily A m4      --1.132    7.78 × 10^−02^   --1.407   6.41 × 10^−03^   2.20 × 10^−19^
  ENSG00000183117   *CSMD1*      CUB and Sushi multiple domains 1                    --1.122    8.02 × 10^−02^   --0.748   1.87 × 10^−02^   2.80 × 10^−05^
  ENSG00000113739   *STC2*       Stanniocalcin 2                                     --1.108    7.78 × 10^−02^   --1.116   6.61 × 10^−03^   2.50 × 10^−08^
  ENSG00000172995   *ARPP21*     cAMP-regulated phosphoprotein 21                    --1.078    8.17 × 10^−02^   --1.089   5.49 × 10^−03^   1.30 × 10^−04^
  ENSG00000137801   *THBS1*      Thrombospondin 1                                    --1.041    7.78 × 10^−02^   --1.020   3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000163075   *CFAP221*    Cilia flagella-associated protein 221               --1.024    7.78 × 10^−02^   --1.135   3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000000005   *TNMD*       Tenomodulin                                         --0.975    7.78 × 10^−02^   --0.768   5.36 × 10^−03^   2.20 × 10^−16^
  ENSG00000158714   *SLAMF8*     SLAM family member 8                                --0.975    9.79 × 10^−02^   --0.892   5.58 × 10^−02^   4.80 × 10^−07^
  ENSG00000186439   *TRDN*       Triadin                                             --0.972    9.70 × 10^−02^   --1.188   1.24 × 10^−02^   2.20 × 10^−16^
  ENSG00000178826   *TMEM139*    Transmembrane protein 139                           --0.943    7.78 × 10^−02^   --1.049   1.47 × 10^−02^   8.90 × 10^−14^
  ENSG00000099957   *P2RX6*      Purinergic receptor P2 × 6                          --0.919    7.78 × 10^−02^   --1.229   5.22 × 10^−03^   1.60 × 10^−10^
  ENSG00000110092   *CCND1*      Cyclin D1                                           --0.893    7.78 × 10^−02^   --0.804   4.30 × 10^−03^   2.20 × 10^−16^
  ENSG00000164188   *RANBP3L*    RAN binding protein 3 like                          --0.868    7.78 × 10^−02^   --1.020   6.41 × 10^−03^   2.20 × 10^−16^
  ENSG00000109846   *CRYAB*      Crystallin *α*B                                     --0.858    7.78 × 10^−02^   --0.935   3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000117154   *FCGBP*      Immunoglobin superfamily member 21                  --1.3181   8.97 × 10^−02^   --0.921   4.49 × 10^−02^   8.40 × 10^−08^
  ENSG00000188778   *ADRB3*      Adrenoceptor *β*3                                   --0.824    9.09 × 10^−02^   --0.720   4.82 × 10^−03^   2.20 × 10^−16^
  ENSG00000102359   *SRPX2*      Sushi repeat containing protein, X-linked 2         --0.816    7.78 × 10^−02^   --0.852   3.98 × 10^−03^   4.90 × 10^−31^
  ENSG00000173641   *HSPB7*      Heat shock protein family B (small) m7              --0.811    7.78 × 10^−02^   --0.813   3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000117594   *HSD11B1*    Hydroxysteroid 11-*β* dehydrogenase 1               --0.803    8.99 × 10^−02^   --0.704   2.54 × 10^−02^   2.20 × 10^−16^
  ENSG00000147852   *VLDLR*      Very-low-density lipoprotein receptor               --0.767    8.17 × 10^−02^   --0.883   4.82 × 10^−03^   2.20 × 10^−16^
  ENSG00000077274   *CAPN6*      Calpain 6                                           0.76       7.78 × 10^−02^   0.777     3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000169710   *FASN*       Fatty acid synthase                                 0.769      8.58 × 10^−02^   0.727     5.49 × 10^−03^   2.20 × 10^−16^
  ENSG00000206384   *COL6A6*     Collagen type VI *α*6 chain                         0.772      7.78 × 10^−02^   0.903     4.55 × 10^−03^   2.20 × 10^−16^
  ENSG00000183798   *EMILIN3*    Elastin microfibril interfacer 3                    0.811      9.27 × 10^−02^   0.449     5.96 × 10^−02^   9.30 × 10^−05^
  ENSG00000081760   *AACS*       Acetoacetyl-CoA synthetase                          0.816      8.60 × 10^−02^   0.783     7.52 × 10^−03^   2.20 × 10^−16^
  ENSG00000166126   *AMN*        Amnion-associated transmembrane protein             0.855      7.78 × 10^−02^   0.568     7.63 × 10^−02^   1.70 × 10^−04^
  ENSG00000112394   *SLC16A10*   Solute carrier family 16 member 10                  0.866      7.78 × 10^−02^   1.447     3.98 × 10^−03^   8.60 × 10^−13^
  ENSG00000060709   *RIMBP2*     RIMS binding protein 2                              0.87       9.10 × 10^−02^   0.708     1.12 × 10^−02^   2.20 × 10^−16^
  ENSG00000253379   *EYA1*       EYA transcriptional coactivator and phosphatase 1   0.902      7.78 × 10^−02^   1.419     3.98 × 10^−03^   1.50 × 10^−17^
  ENSG00000099194   *SCD*        Stearoyl-CoA desaturase                             0.911      7.78 × 10^−02^   1.100     3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000124003   *MOGAT1*     Monoacylglycerol *O*-acyltransferase 1              0.912      8.02 × 10^−02^   1.213     3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000168702   *LRP1B*      LDL receptor-related protein 1B                     0.919      7.78 × 10^−02^   0.717     5.44 × 10^−02^   2.20 × 10^−16^
  ENSG00000130208   *APOC1*      Apolipoprotein C1                                   0.92       7.78 × 10^−02^   0.870     2.76 × 10^−02^   2.20 × 10^−16^
  ENSG00000140284   *SLC27A2*    Solute carrier family 27 member 2                   0.926      9.88 × 10^−02^   1.132     1.32 × 10^−02^   2.20 × 10^−16^
  ENSG00000113494   *PRLR*       Prolactin receptor                                  0.979      7.78 × 10^−02^   1.080     5.27 × 10^−03^   2.20 × 10^−16^
  ENSG00000198963   *RORB*       RAR-related orphan receptor B                       0.986      7.78 × 10^−02^   0.877     5.49 × 10^−03^   2.20 × 10^−16^
  ENSG00000138678   *GPAT3*      Glycerol-3-phosphate acyltransferase 3              1.065      7.78 × 10^−02^   1.087     9.85 × 10^−03^   2.20 × 10^−16^
  ENSG00000164879   *CA3*        Carbonic anhydrase 3                                1.072      7.78 × 10^−02^   1.327     7.52 × 10^−03^   2.20 × 10^−16^
  ENSG00000135744   *AGT*        Angiotensinogen                                     1.087      7.78 × 10^−02^   1.116     4.82 × 10^−03^   2.20 × 10^−16^
  ENSG00000143365   *RORC*       RAR-related orphan receptor C                       1.098      7.78 × 10^−02^   1.660     3.98 × 10^−03^   2.20 × 10^−16^
  ENSG00000145428   *RNF175*     Ring finger protein 175                             1.098      7.78 × 10^−02^   1.119     1.87 × 10^−02^   7.60 × 10^−09^
  ENSG00000170522   *ELOVL6*     ELOVL fatty acid elongase 6                         1.167      7.78 × 10^−02^   1.204     8.19 × 10^−02^   2.20 × 10^−16^
  ENSG00000160339   *FCN2*       Ficolin 2                                           1.181      7.78 × 10^−02^   1.294     5.36 × 10^−03^   2.20 × 10^−16^
  ENSG00000015520   *NPC1L1*     NPC1-like intracellular cholesterol transporter 1   1.276      7.78 × 10^−02^   0.765     3.50 × 10^−02^   5.50 × 10^−05^
  ENSG00000103460   *TOX3*       TOX high-mobility group box family member 3         1.282      7.78 × 10^−02^   1.378     8.73 × 10^−02^   1.70 × 10^−11^
  ENSG00000172425   *TTC36*      Tetratricopeptide repeat domain 36                  1.295      7.78 × 10^−02^   1.260     6.41 × 10^−03^   3.50 × 10^−10^

Genes passing an FDR of 0.1 and a log~2~ FC threshold of 0.75 are reported here. Differential expression was tested by using a logistic regression model correcting for age and sex followed by a Wald test to assess the statistical significance of the coefficient of interest. As no sex interaction was found, association was evaluated without interaction term. Benjamini--Hochberg multiple testing correction was applied within the fitted model on the derived *P* values (FDR). Correlation tests between RNA-seq and Nanostring gene quantification were performed using a nonparametric Spearman correlation test. CT, constitutional thinness; FC, fold change; FDR, false discovery rate; RNA-seq, RNA sequencing.

Short-term overfeeding did not result in a different metabolic response in CT subjects {#sec3-4}
--------------------------------------------------------------------------------------

To investigate whether the metabolic response to overfeeding was different in CT compared with controls, the participants were next given a 600-kcal surplus to their diet for 14 d (300-mL shake in the evening, containing 30 g protein, 72 g carbohydrate, and 21 g fat). Overall compliance to the overfeeding regimen was confirmed by a significant increase in urea excretion in both groups relative to the baseline (FC 1.22, *P* \< 0.001) (**[Supplemental Table 6](#sup1){ref-type="supplementary-material"}**). Both groups gained a small but significant amount of weight during the overfeeding (*P* \< 0.001), but no significant difference in weight gain was observed between the 2 groups (**[Supplemental Figure 8](#sup1){ref-type="supplementary-material"}**). Even though some clinical and energy balance parameters were altered upon overfeeding ([Supplemental Table 6](#sup1){ref-type="supplementary-material"}), no differences in response to the overfeeding were observed in CT individuals compared with controls. Similarly, tissue respiration ([Figure 1B](#fig1){ref-type="fig"}, [Supplemental Figure 6](#sup1){ref-type="supplementary-material"}) and transcriptomic profiling (**[Supplemental Figures 9](#sup1){ref-type="supplementary-material"}** and **[10](#sup1){ref-type="supplementary-material"}**), as well as plasma proteomics ([Supplemental Table 3](#sup1){ref-type="supplementary-material"}), all showed some differences upon the intervention, but none demonstrated a differential response to the overfeeding between CT individuals compared with controls. Together, these results demonstrate that the molecular response to the overfeeding is similar in CT individuals compared with controls and that the main molecular differences observed at baseline remain present after the overfeeding.

Discussion {#sec4}
==========

CT individuals are a unique group of people who, despite our modern world\'s obesogenic environment, are characterized by very low absolute fat and lean body mass. However, unlike lipodystrophic people, their relative fat mass is in a similar range to normal-weight people, and they do not exhibit hypertriglyceridemia or have any evidence of ectopic lipid accumulation. They are therefore considered healthy people. Results from our study show that there is no sign of gastrointestinal fat malabsorption, as evidenced by a similar amount of fat in the stool. In the present study, we show for the first time, to our knowledge, that there are distinct molecular differences in the adipose tissue of CT individuals compared with that of normal-weight people: the adipocytes of CT individuals are smaller, contain a higher number of mitochondria that are more active, and have a distinct transcriptomic profile. CT people also have lower lean body mass, and the lower urinary secretion of creatinine, uric acid, and urea in CT individuals is associated with this lower lean mass. A reduced percentage of oxidative type I fibers and cytochrome C oxidase activity within type I fibers has been reported in skeletal muscle samples from CT females ([@bib27]). Yet, the activity of other major enzymes playing a role in the pre- and post-mitochondrial respiratory chain activity was not different ([@bib5], [@bib27]). Our data on respiration or transcriptomic profiles of the entire skeletal muscle samples could not confirm any significant differences in oxidative potential or mitochondrial activity in muscle from CT individuals. The results from our present study therefore point toward a difference in lipid metabolism in CT and not a systemic difference in mitochondrial biogenesis.

Interestingly, not only is the total amount of mitochondria per adipocyte greater in CT individuals, but respiration assays also showed a specifically higher activity of mitochondrial CII in both male and female adipose tissue, resulting in elevated electron transport chain activity. This greater CII flux rate in CT individuals indicates a higher fuel supply through fatty acid *β*-oxidation in mitochondrial bioenergetics, consistent with the upregulation of the fatty acid oxidation pathway from the transcriptomic analysis. Moreover, higher systemic fasting lipid oxidation rates were observed by indirect calorimetry. Dietary macronutrient levels and composition were very similar between the groups and thus most likely do not contribute to these observed oxidation rate differences. Studies in humans with extreme altered fat mass, such as obese and lipodystrophic people, have shown mitochondrial dysfunction in white adipose tissue ([@bib28]), resulting in reduced oxidative capacity, which can link to the associated metabolic complications. In addition, a recent study elegantly showed that a lower capacity to mobilize adipose tissue through lipolysis is a strong factor of weight gain ([@bib29]). Differences in mitochondrial energy efficiency have also been proposed to contribute to interindividual variability in weight gain in response to overfeeding ([@bib30]). On the other hand, increased mitochondrial activity has been suggested to be a mechanism by which caloric restriction promotes health benefits ([@bib31]). Induction of fatty acid *β*-oxidation and mitochondrial oxidative capacity through CII, with a shift from carbohydrate to fat utilization, was suggested to derive energy during caloric restriction, thereby reducing production of reactive oxygen species ([@bib31]), as well as link to a lean phenotype ([@bib32]).

Over the past decade, there have been several studies exploring a potential role of a low REE and low body core temperature as "thrifty" metabolic traits in the onset of obesity ([@bib33], [@bib34]), yet conflicting results have been reported ([@bib35], [@bib36]). Inversely, it could be that CT individuals have a high REE and/or a higher temperature set point, which could lead to differences in metabolic efficiency. REE and TEE were found to be lower in CT individuals than controls, confirming earlier results ([@bib5], [@bib6]). Yet, after correction for fat-free mass, the REE difference was blunted, as was also found in the previous report ([@bib6]). Tc is more independent of body size or composition (as it is reflecting a central nervous system set point) ([@bib36]), and hence it could provide additional valuable information on metabolic differences in CT individuals. Our results at baseline suggest indeed that CT individuals have a slightly higher Tc. However, a recent study pointed out the difficulty of reliably measuring Tc in individuals ([@bib37]). For the moment, we cannot firmly conclude whether CT people have undergone any metabolic adaptation or have different Tc, and more in-depth analysis of energy homeostasis could be valuable.

Pathway analyses of the adipose tissue gene expression profiles demonstrated an increase not only in lipid catabolism in CT but surprisingly also in lipid biosynthesis. This suggests the presence of higher futile lipid cycling, potentially associated with the observed increased mitochondrial activity and buildup of smaller adipocytes. Efficient adipocyte turnover and function are key determinants of a healthy metabolic profile ([@bib38]). Studies of caloric restriction but also mild cold exposure demonstrated increased fatty acid synthesis alternating with increased fatty acid oxidation ([@bib39], [@bib40]), which could be similar to what we observe in CT. Given that CT individuals tend to snack more often and have constant hunger, we propose that they have an increased whole-body lipid metabolism more active all the time, leading to higher basal energy expenditure. In plasma, no differences in lipid metabolic markers could be detected, suggesting a tight homeostatic regulation. This observation strengthens our finding of an adipose tissue--specific phenotype, as well as augmented futile lipid cycling. Indeed, in contrast to increased lipid oxidation alone, an increase in lipid turnover results in an equilibrated lipid balance, and thus net circulating lipid biomarkers would remain equal. Of note, from the untargeted plasma proteomic profiling, we found 3 plasma proteins with consistent increased levels in CT individuals, one of which is DBH. This intraneuronal enzyme plays a key role in catecholamine synthesis, and its blood levels are used as an index of sympathetic nerve activity ([@bib41]). An inverse correlation between serum DBH levels and obesity has been previously described ([@bib42]), and DBH knockout mice have reduced leptin-stimulated lipolysis ([@bib43]). Even though we did not find any differences in blood (or) metadrenaline levels, we speculate that increased levels of blood DBH in CT individuals could be a potential indicator for increased sympathetic neuroadipose connections linking to increased lipid metabolism in CT individuals.

Another hypothesis often put forward is that CT people might have enhanced BAT activity. An earlier study on CT people reported indeed some higher BAT activity under thermoneutral conditions ([@bib44]). Even though we did not observe an increase in uncoupled respiration or UCP1 expression in the sWAT of CT individuals, the presence of beige cells cannot be fully excluded. Indeed, these cells are quiescent and can undergo beiging (increased UCP1 expression to levels similar to that in BAT, as well as morphological transformation) following *β*-adrenergic stimulation ([@bib45]).

Overfeeding of the individuals led to metabolic changes that were similar in the CT and control groups, as evidenced by similar body weight increase but also in biochemical measurements and transcriptomic profiles. This similar response to the overfeeding is somewhat different from what was observed before, in which a resistance to weight gain upon overfeeding was described in CT individuals ([@bib6]). However, our current intervention protocol differs in several ways from the previous one: overfeeding time was twice as long in the earlier study (4 instead of 2 wk), and the latter consisted mainly of fat overfeeding, while our intervention consisted of a more nutritionally balanced overfeeding (600-kcal excess, with 31.5% fat, 20% protein, and 48.5% carbohydrates). Overall, the participants gained a small amount of weight, and some metabolic changes occurred in lowering triglyceride levels and increasing insulin levels. These rapid changes in lipid metabolism with a shift toward storage of lipids and increased insulin levels have been previously described to occur in the early phase of weight gain during overfeeding ([@bib46]). Longer intervention might be necessary to better evaluate whether CT individuals respond in a metabolically different way to overfeeding.

Conclusions {#h2content1564461500222}
-----------

We show for the first time, to our knowledge, that persistent low body weight in humans is associated with features in the white adipose tissue that are opposite to that of obese patients. In particular, we observed increased lipid oxidation, potentially higher futile cycling of fatty acids, upregulation of mitochondrial function, and many genes differentially regulated and associating with positive metabolic profiles. Our findings postulate an important role of mitochondria as local regulators of adiposity and weight. Male and female CT individuals appear to share most metabolic characteristics. Understanding the molecular mechanisms that allow CT individuals to maintain their extremely low body weight despite a challenging environment may allow a more targeted approach for weight management and treatment strategies.
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